Forbes July 11, 2024
Only 15% of patients prescribed GLP-1s for weight loss were still taking the medications two years later, according to an analysis of pharmacy claims posted on July 10th by the pharmacy benefit manager, Prime Therapeutics. A flurry of other studies published recently show relatively high percentages of patients dropping out as early as four weeks into treatment and that discontinuation increases over time. Evidence that many people may stop their use of obesity drugs not long after starting therapy casts doubt about the sustainability of weight loss to achieve long-term positive health outcomes.
There is high demand for obesity medications known as glucagon-like peptide-1 agonists, or GLP-1s. In conjunction with an appropriate diet and exercise regimen, GLP-1s can provide substantial...
Today's Sponsors
Today's Sponsor